Decoupling the Role of Ubiquitination for the Dislocation Versus Degradation of Major Histocompatibility Complex (MHC) Class I Proteins during Endoplasmic Reticulum-associated Degradation (ERAD)*

Xiaoli Wang¹, Y. Y. Lawrence Yu, Nancy Myers, and Ted H. Hansen²
From the Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri 63110

Background: Whether ubiquitination of endoplasmic reticulum-associated degradation substrate is required for dislocation remains unresolved.

Results: Mutant major histocompatibility complex I (MHC) heavy chains lacking tails or lysine residues are dislocated in a deubiquitinating enzyme-dependent manner.

Conclusion: Ubiquitination of MHC heavy chains is not required for dislocation as it is required for degradation.

Significance: Our data support a model that dislocation and degradation require two mechanistically distinct ubiquitination events.

*This work was supported, in whole or in part, by National Institutes of Health Grant AI019687.
¹To whom correspondence may be addressed: 660 S. Euclid Ave., St. Louis, MO 63110. Tel.: 314-362-3972; Fax: 314-362-4137; E-mail: xiwang@pathology.wustl.edu.
²To whom correspondence may be addressed: 660 S. Euclid Ave., St. Louis, MO 63110. Tel.: 314-362-2716; Fax: 314-362-4137; E-mail: hansen@pathology.wustl.edu.

Endoplasmic reticulum-associated degradation (ERAD)³ is the major mechanism by which cells get rid of unwanted proteins that fail to pass quality controls in the secretory pathway or are in an excess in metabolic regulation. Mechanistically the ERAD of substrates can be divided into four steps: recognition, retrotranslocation (dislocation), ubiquitination, and degradation. Significant progress has been made in identifying critical components for each of these four steps of ERAD. Notably, however, the molecular mechanism of substrate dislocation remains largely unknown (1, 2). Of particular recent interest has been defining the specific role substrate ubiquitination plays in dislocation (3).

Using a highly evolutionarily conserved enzymatic cascade of an E1 activating enzyme, an E2 conjugating enzyme, and an E3 ligase, substrates are typically coupled with ubiquitin (Ub) on a Lys residue (4). Extending this initial Ub conjugation, a polyubiquitin chain can be built by E2/E3 pairs adding sequential Ub moieties with selected linkage. Substrates with polyubiquitin chains of length greater than 4 moieties typically coupled via Lys³⁸⁻ or Lys¹¹⁻linkage are targeted to the proteasome for degradation (5, 6). Once they reach the proteasome, the Ub-tagged proteins are first deubiquitinated by deubiquitinating enzymes (DUBs) in or associated with the 19S regulatory particle that releases Ub for recycling and allows the substrate to enter the narrow pore of the 20S core for degradation (7–10). In addition to proteasome targeting, Ub conjugation on substrate is thought to be a prerequisite for dislocation. Of note, although different ERAD substrates are associated with different multi-mislocated degradation protein complexes, an ER membrane-associated E3 ligase is always found as a central component of the dislocation complex (11, 12). The major role of the E3 ligase
within the dislocation complex is to connect the ER luminal chaperone responsible for substrate recognition with its cognate E2 enzyme for substrate ubiquitination. The cytosolic p97 (Cdc48 in yeast) ATPase is then recruited with its cofactors Ufd1 and Npl4 to provide the pulling force for dislocation of ubiquitinated substrates from diverse dislocation complexes (13–16). Binding of a polyubiquitin chain via Ufd1 and Npl4 is required for dislocation of substrate (17). The polyubiquitin chain on the substrate therefore was speculated to serve as a binding handle for association with the p97 complex, whereas hydrolysis of ATP takes place.

Taken together these findings suggest that substrate ubiquitination may be required for complete dislocation. Curiously, however, direct ubiquitination of substrates during dislocation has been difficult to demonstrate (18, 19). Also, it is not clear whether ubiquitination plays the same role in dislocation of disparate substrates that may use different molecular mechanisms of dislocation. For example, it is conceptually easy to envisage how the cytoplasmic domain of a membrane protein can be ubiquitinated by the cytosolic ubiquitination machinery and how this modification could play a critical role in recruiting the p97 complex to extract the substrate from the ER membrane. However, in some cases potential Ub acceptor sites in the cytosolic domain or even a cytoplasmic tail itself are dispensable for dislocation of certain model ERAD substrates (20–22). In these scenarios as well as for soluble substrates in the ER lumen, an initial movement (a so-called partial dislocation) prior to their complete extraction has been proposed to allow ubiquitination to occur in the cytosol. In support of this partial dislocation model, Kopito and co-workers (23) recently found that Derlin proteins are inactive members of the rhomboid family of intramembrane proteases. Mutations in the rhomboid domain of Derlin1 stabilized mutant α1-antitrypsin, a soluble model ERAD substrate, on the cytosolic face of the ER membrane without interfering with p97 binding (23). These findings suggested that a soluble substrate is first transferred from the ER lumen to the membrane after which Derlin1 and p97 combine to complete dislocation. The role of substrate ubiquitination in this model remained undefined.

Intriguingly, several recent studies suggest that a p97-associated deubiquitinating step is required for dislocation of intact soluble or membrane proteins from the ER. For example, the newly discovered chemical inhibitor Eeyarestatin 1 (Eer1) was found to interfere with p97-associated DUB activity (24) and this drug could block dislocation of orphan TCRα and US11-induced dislocation of major histocompatibility complex class I (MHCI) heavy chain (25). Additionally, enzymatically inactive YOD1, a p97 associated DUB, stabilized truncated ribophorin (Ri332, a soluble substrate of ERAD), and TCRα in the ER, whereas expression of a chimeric protein with the UBX domain of YOD1 for p97 association and the DUB domain of EBV facilitated the release of stalled Ri332 and TCRα into the cytosol. However, this chimeric protein also blocked proteasome-mediated degradation suggesting p97-associated deubiquitination is necessary for protein dislocation but premature removal of a polyubiquitin chain from the substrate before proteasome impairs proteasome-mediated degradation (26–28). These combined observations led to the proposal that two sequential rounds of ubiquitination may be required for ERAD of at least a subset of substrates. The initial round of ubiquitination/deubiquitination would be required for substrate to pass through the narrow pore of p97 to complete dislocation and the second round of ubiquitination/deubiquitination is required for substrate to pass through the proteasome to be degraded (8). Although appealing, this model remains to be experimentally proven. A key question to test in this model or any ERAD model is whether the substrate is the direct target of ubiquitination and deubiquitination prior to or during dislocation.

One of the most extensively studied substrates used to probe the mechanisms underlying ERAD in mammals is MHCI heavy chain (HC), a type 1 integral membrane protein (29, 30). These investigations have been facilitated by viral immune evasion proteins that induce rapid ERAD of HC, such as US2 and US11 of human cytomegalovirus and mK3 of murine γ herpesvirus 68 (29, 30). Interestingly, although all three of these viral proteins target HC for degradation by the proteasome, the mechanisms by which HCs are recognized, ubiquitinated, and dislocated are distinct. For example, US2-induced ERAD of HC depends on TRC8 E3 ligase and signal peptide peptidase (31, 32), whereas US11-mediated dislocation of HCs is dependent upon SEL1L and Derlin1 (33, 34). Although associated with the HRD1 E3 ligase complex, the functional dependence of US11 on HRD1 or any other ER-associated E3 ligase has not been demonstrated (35–37). Furthermore, based on studies of Lysless HC, direct Ub conjugation on HC appears to be required for dislocation of HC by US2 but not by US11 (18). Given that US11 can directly interact with Derlin1 that is essential for recruiting p97 and dislocation (23, 33, 34), US11-induced dislocation could conceivably bypass the need for substrate ubiquitination. Different from US2- and US11-induced ERAD of HC, mK3 facilitates the Ub conjugation on the cytoplasmic tail of HCs (38). This finding implies that mK3 induces the extraction of HC from the ER vectorially by its C-terminal tail. Thus studies of these 3 viral proteins targeting ERAD of HC accentuate current dogma that there are multiple mechanisms to induce dislocation. But after dislocation all ERAD substrates are thought to use a similar mechanism for degradation (1).

Interestingly, recent studies of physiologic ERAD of HC demonstrate that it uses a mechanism distinct from that induced by any of the above viral immune evasion proteins. Quality control-induced ERAD of incompletely assembled HC molecules has been studied using cells deficient in β2m, the MHCI light chain, or cells deficient in the transporter associated with antigen processing (35, 39, 40). For example, Burr et al. (35) recently showed that HRD1 and UBE2J1 play an essential role in the ERAD of non-β2m assembled HC. However, in this study whether direct ubiquitination of HC is required for dislocation was not addressed. A challenge in determining the role substrate ubiquitination plays in dislocation versus degradation results from the limited substrates undergoing ERAD at a given time relative to the total pool of HCs. However, the study by Burr et al. (35) clearly demonstrates that viral proteins do not faithfully mimic early mechanisms of substrate ubiquitination and dislocation induced by physiologic ERAD.
Non-substrate Deubiquitination Required for ERAD Dislocation

To selectively probe the mechanism of dislocation versus degradation of HC under physiological conditions, we adapted a cytosolic site-specific biotinylation system that allows the N terminus of HC to be biotinylated once it is exposed to the cytosol (41). Using this system, combined with pharmacological inhibition of p97 and/or proteasome, we were able to quantitatively monitor the dislocation of membrane-bound, glycosylated HCs to the cytosol as well as the degradation of post-dislocated HCs in the cytosol. We found that inhibition of DUB activity leads to an accumulation of biotinylated MHCI molecules in the ER membrane, however, neither the tail of HC nor the Lys residues in the luminal site are required for the dislocation of these HCs. Nevertheless, their ectodomain lysines are clearly required for degradation of the HCs by the proteasome. These findings support the model that during quality control induced ERAD, direct ubiquitination of HC substrates is not required for dislocation, but is clearly required for degradation.

EXPERIMENTAL PROCEDURES

Cell Lines—Murine B6/WT3 (WT3, H-2b) embryonic fibroblasts and triple knock-out fibroblasts (Kb−/−Db−/−β2m−/−, 3KO) were described previously (42). 293T cells (43) were used for production of retrovirus. All cells were maintained in complete RPMI 1640 or DMEM supplemented with 10% fetal calf serum (HyClone) as described (44). Retrovirus-containing supernatants were produced with transient transfection of 293T cells using the pVpack vector system (Stratagene).

DNA Constructs—Retroviral BirA expressing vector pMIP.cyt-BirA was constructed by subcloning the coding sequence of an Escherichia coli—derived BirA ligase from pDisplay.BirA ligase (kindly provided by Dr. Mike Diamond, Washington University) into a pMSCV.ires.Puro (pMIP) retroviral expression vector (gift of Dr. L. Lybarger, University of Arizona). The ER-BirA expression vector pMIP.ER-BirA was generated by fusing a signal peptide from the murine Ighv14–3 gene to the N terminus and a KDEL ER-retention signal to the C terminus of the birA ligase gene in the construct pMIP.cyt-BirA. A-15 amino acid (GLNDIFEAQKIWHE) biotin acceptor peptide (BAP) (45) + an NheI site (encoding AS) were placed between the Ld signal peptide and the 1st residue of the mature Ld polypeptide in the pMIN.Ld vector described previously (44) to generate the retroviral BAP-Ld expression construct. The Ld mutants including Ld tailAK (with all 3 Lys residues on the cytoplasmic tail replaced by Arg), Ld tailAKCST (with KCST residues on the tail mutated), LdΔtail (with tail sequence after the basic cluster RRRRNT deleted), and LdΔK (with all 13 Lys residues on the entire Ld molecule replaced by Arg) have been described previously (38). The correct sequences for all of the constructs were confirmed by DNA sequencing.

Antibodies and Reagents—Rabbit antisera to the cytoplasmic tail of Ld (Ra20873) and mAbs to the ectodomain of Ld (30-5-7 and 64-3-7) were described previously (44, 46). Antibody to Ub (P4D1), β-actin (AC-74), and rabbit anti-calnexin (SPA-860) were purchased from Santa Cruz, Sigma, and Enzo, respectively. PR-619, DBeQ, and Eer1 were obtained from LifeSensors, Sigma, and EMD Millipore, respectively.

Cell Permeabilization and Fractionation—After treatment with proteasome or DUB inhibitors as indicated and detachment by trypsin-EDTA, the cells were washed with PBS twice and resuspended in PBS containing 20 μM iodoacetamide (Sigma), protease inhibitors (Complete Mini, Roche Applied Science), and 0.02% digitonin (Wako Chemicals, Richmond, VA) at 0.5–1.0 × 10⁷/ml and incubated on ice for 20 min. Soluble cytosolic proteins in the supernatant and membrane proteins in the pellet were separated by centrifugation of digitonin-treated cells at 18,000 × g, 4°C for 15–20 min.

Immunoprecipitation and Immunoblot—Cells or pellet fractions were lysed in PBS buffer containing 1% Nonidet P-40, 20 mM iodoacetamide and protease inhibitors (Complete Mini, Roche). Postnuclear lysates or supernatant fractions were then incubated at 4°C overnight with Ld mAbs and protein A-Sepharose (Sigma). After washing 4 times with 0.15% Nonidet P-40/PBS/iodoacetamide, precipitates were eluted with 1× LDS sample loading buffer (Invitrogen), and β-mercaptoethanol was added to a final concentration of 5% where indicated. Immunoblot was performed following SDS-PAGE separation of precipitated proteins or cell lysates. Specific proteins were visualized by standard enhanced chemiluminescence HRP substrate (ECL, Thermo) or supersensitive ECL (Immum-Star WesternC, Bio-Rad) as indicated. For PNGase F treatment, after washing, the immunoprecipitates were eluted in the denaturing buffer (0.5% SDS, 1% β-mercaptoethanol) at 95°C for 5 min and then incubated at 37°C for 1 h in 50 mM sodium phosphate, pH 7.5, containing 1% Nonidet P-40 and 5 units of PNGase F (New England Biolabs). For proteinase K treatment, cells were incubated on ice with 5 μg/ml of proteinase K (Invitrogen) for 20 min. After the digestion was stopped by addition of 1 mM PMSF the cells were lysed and subjected to immunoprecipitation. Densitometry was done using ImageJ (NIH).

RESULTS

A Biotinylation System Enables Detection of a Small Fraction of HC Substrates Subjected to ERAD—The dislocation of HC proteins, like other ERAD substrates, is typically monitored by blocking proteasome activity and detecting a small fraction of the total HCs as soluble, deglycosylated forms in the cytosol by immunoblot. Prior to deglycosylation by cytosolic N-glycanase this small fraction of the HCs in the ER membrane cannot be distinguished from the majority of HC molecules destined for surface expression along the secretory pathway. To directly and quantitatively monitor dislocation of HC, an in vivo cytosolic site-specific biotinylation system was developed. In this system E. coli—derived BirA biotin ligase (cyt-BirA) (47) was co-expressed in mouse embryonic fibroblast cells with the HC molecule (Ld) having a BAP (45) fused to its N terminus. Because BirA without a signal peptide is expressed exclusively in the cytosol, the N-terminal BAP-tagged Ld molecules (BAP-Ld) can be biotinylated only when their N termini are exposed to the cytosol after being dislocated (or partial dislocated) (Fig. 1A, panels I and III). Of note the BAP tag on the Ld molecules does not disrupt its native folding or surface expression.

To validate this system, an ER expressing BirA (ER-BirA) with a signal peptide fused to the N-terminal end and a KDEL ER-retrieval signal at the C-terminal end was engineered and
co-expressed with BAP-Ld in murine fibroblasts lacking classical HC and β2m. Ld molecules were retrieved from the cell lysates by precipitation with anti-Ld antibodies. Total Ld HCs and biotinylated Ld HCs (*Ld) in the precipitates were then determined by blotting with anti-Ld and streptavidin-HRP conjugates (SA-HRP), respectively, and visualized by the standard enhanced chemiluminescence substrate (ECL) for HRP. Under such conditions the BAP-Ld molecules were clearly biotinylated by ER-BirA, but not by cyt-BirA, although they are equally expressed (Fig. 1, A, panel II, and B). To detect the steady-state level of HCs being removed from the ER to the cytosol under more physiological conditions, WT3 cells with
β2m and endogenous MHCI proteins were co-transduced with cyt-BirA and BAP-Ld. These cells were treated with proteasome inhibitor MG132 followed by permeabilization to separate the cytosolic fraction in the supernatant (S) from the membrane fraction in the pellet (P). The lysate blots for the ER membrane protein calnexin and the cytosolic protein β-actin verified the fractionation (Fig. 1C, right panel). Ld molecules captured by immunoprecipitation of Ld from the two fractions were blotted by SA-HRP and visualized using supersensitive ECL. Using this approach, a band corresponding to glycosylated Ld molecules was readily detected in the membrane fraction with or without MG132 treatment (Fig. 1C, lanes 2 and 4). These molecules likely represent HCs whose N termini have been exposed to the cytosol, but remain membrane associated (i.e. having undergone partial dislocation). Additionally in the presence of proteasome inhibitor, more than half of the Ld molecules in the cytosol displayed a faster migration rate (Fig. 1C, lane 1); and these faster migrating Ld molecules were deglycosylated HCs based on their unchanged position in the gel after PNGase F treatment (Fig. 1D, lane 4 versus lane 2). Thus these molecules are HCs that have been fully dislocated to the cytosol. Of note, some of the deglycosylated Ld molecules were detected in the P fraction (Fig. 1C, lane 2) as well. These P-associated Ld molecules are likely residual cytosolic proteins resulting from incomplete depletion during fractionation because residues of typical cytosolic proteins such as β-actin could also be observed in the P fraction (Fig. 1C, right panel). The amount of these residual deglycosylated Ld forms in the P fraction varied depending on whether a wash step was conducted following permeabilization and centrifugation.

To determine the fraction of HC having undergone dislocation, the same samples were also blotted for Ld rather than SA-HRP. Densitometry comparisons of Fig. 1C, lanes 5 and 6, indicated that less than 1% of total Ld was detected as soluble forms in the cytosol. Unfortunately, it was not possible to estimate the percentage of membrane-bound Ld that was biotinylated because glycosylated forms of Ld and Ld could not be distinguished (Fig. 1C, lanes 2 and 4 versus lanes 6 and 8). Furthermore, by treating Ld molecules with β-mercaptoethanol, the presence of intracellular disulfide bonds in Ld was determined. Although the glycosylated Ld band shifted up under reducing conditions (Fig. 1E, lanes 3 and 4), the band corresponding to deglycosylated Ld molecules remained unchanged after β-mercaptoethanol treatment (Fig. 1E, lane 4 versus lane 2). These findings demonstrated that glycosylated Ld forms remain folded, but the deglycosylated Ld species are unfolded. Thus reduction of disulfide bonds may be a prerequisite for complete dislocation of HC as implicated by studies of other authors (48–50).

To determine whether the glycosylated Ld molecules have their N termini continuously extended in the cytosol, proteinase K sensitivity was tested. As shown in Fig. 1F, the cytoplasmic tail of membrane-bound Ld molecules was sensitive to proteinase K treatment as evidenced by a smaller band that could be detected by antibodies specific for the ectodomain of Ld but not by antibodies specific for the tail of Ld (Fig. 1F, lane 4 versus lane 6). By contrast, N termini of membrane-bound Ld appeared to be resistant to treatment because the strength of the SA-HRP signal for the N-terminal biotin was unchanged (Fig. 1F, lane 2 versus 1). This result suggests that at steady-state the majority of the membrane-bound Ld have their N termini in the ER lumen and the C termini in the cytosol. How these HCs expose their N termini to the cytosol to get biotinylated by the cyt-BirA and subsequently retrieve their type I integral membrane protein topology is intriguing and may reflect repeated refolding attempts during ER quality control. Alternatively, the N terminus of membrane-bound Ld may reside on the cytosolic side of the ER membrane, but be protected against proteinase K cleavage by associated proteins involved in dislocation. Regardless of the membrane orientation of glycosylated Ld, most of these molecules are fated for ERAD. This conclusion is supported by steady-state data showing that more than half of the Ld molecules are dislocated within a short time after blockade of proteasome function (Fig. 1C). In addition, kinetically, in a cycloheximide (CHX) chase experiment, the decrease over time in the level of membrane-bound, glycosylated Ld was correlated with the increase in the level of deglycosylated Ld in the cytosol (Fig. 1G). Thus most membrane-bound Ld molecules appear to be HCs sentenced to ERAD that are continuously removed from the ER.

**Dislocation of BAP-Ld Is Dependent of DUB Activity**—As mentioned in the Introduction, DUB function has been impli-

---

**FIGURE 1. A cytosolic site-specific biotinylation system allows detection of limited MHCI HCs subject to ERAD.** A, schematic depiction of site-specific biotinylation of N-terminal BAP-tagged Ld HC in cells. **Panel a,** a type I transmembrane protein, BAP-Ld, cannot be biotinylated by cytosolic expressed BirA ligase (cyt-BirA); **Panel b,** BAP-Ld can be biotinylated by ER expressed BirA (ER-BirA); **Panel III,** only partially or completely dislocated BAP-Ld can be biotinylated by cyt-BirA, B, mouse 3KO cells were first transduced with the BAP-Ld then co-transduced with either cyt-BirA or ER-BirA. BAP-Ld molecules were immunoprecipitated (IP) using mAb 30-5-7 and 64-3-7. The precipitates were separated by SDS-PAGE and blotted to detect biotinylated BAP-Ld (*Ld*). This result suggests that at steady-state the majority of the membrane-bound *Ld* have their N termini in the ER lumen and the C termini in the cytosol. How these HCs expose their N termini to the cytosol to get biotinylated by the cyt-BirA and subsequently retrieve their type I integral membrane protein topology is intriguing and may reflect repeated refolding attempts during ER quality control. Alternatively, the N terminus of membrane-bound *Ld* may reside on the cytosolic side of the ER membrane, but be protected against proteinase K cleavage by associated proteins involved in dislocation. Regardless of the membrane orientation of glycosylated *Ld*, most of these molecules are fated for ERAD. This conclusion is supported by steady-state data showing that more than half of the *Ld* molecules are dislocated within a short time after blockade of proteasome function (Fig. 1C). In addition, kinetically, in a cycloheximide (CHX) chase experiment, the decrease over time in the level of membrane-bound, glycosylated *Ld* was correlated with the increase in the level of deglycosylated *Ld* in the cytosol (Fig. 1G). Thus most membrane-bound *Ld* molecules appear to be HCs sentenced to ERAD that are continuously removed from the ER.
Non-substrate Deubiquitination Required for ERAD Dislocation

FIGURE 2. Inhibition of DUB activity by Eer1 or PR-619 impairs dislocation of *Ld. A, left panel: WT3 cells co-expressing cyt-BirA and BAP-Ld were incubated with Eer1 (10 μM), MG132 (15 μM), or a combination of the two for 5.5 h before collection, permeabilization, and fractionation. *Ld and total Ld from the supernatant or pellet fractions were recovered with anti-Ld and blotted with SA-HRP or Ld mAb 64-3-7/std-ECL. Right panel, lysates from the supernatant or pellet fractions before immunoprecipitation (IP) were blotted (IB) for ubiquitinated proteins to show the effect of DUB or proteasome inhibition. B, cells used in A were incubated with 40 μM MG132 or PR-619, or a combination of the two for 1 h before being subjected to permeabilization and fractionation. The subsequent detections were the same as in A. Similar findings were observed in at least one additional independent experiment.

Inhibition of DUB activity by Eer1 or PR-619 impairs dislocation of *Ld. A, left panel: WT3 cells co-expressing cyt-BirA and BAP-Ld were incubated with Eer1 (10 μM), MG132 (15 μM), or a combination of the two for 5.5 h before collection, permeabilization, and fractionation. *Ld and total Ld from the supernatant or pellet fractions were recovered with anti-Ld and blotted with SA-HRP or Ld mAb 64-3-7/std-ECL. Right panel, lysates from the supernatant or pellet fractions before immunoprecipitation (IP) were blotted (IB) for ubiquitinated proteins to show the effect of DUB or proteasome inhibition. B, cells used in A were incubated with 40 μM MG132 or PR-619, or a combination of the two for 1 h before being subjected to permeabilization and fractionation. The subsequent detections were the same as in A. Similar findings were observed in at least one additional independent experiment.

Eer1 is a newly discovered small molecule inhibitor that blocks dislocation of certain ERAD substrates, but does not prevent proteasome-mediated degradation. More specifically, Eer1 has been proposed to block p97-associated DUB activity (24). To test whether Eer1 can impair dislocation of *Ld, cells co-expressing cyt-BirA and BAP-Ld were treated with Eer1 or MG132 before being permeabilized and fractionated. *Ld molecules in the supernatant or pellet fractions were recovered with anti-Ld and blotted with SA-HRP or Ld mAb 64-3-7/std-ECL. Right panel, lysates from the supernatant or pellet fractions before immunoprecipitation (IP) were blotted (IB) for ubiquitinated proteins to show the effect of DUB or proteasome inhibition. B, cells used in A were incubated with 40 μM MG132 or PR-619, or a combination of the two for 1 h before being subjected to permeabilization and fractionation. The subsequent detections were the same as in A. Similar findings were observed in at least one additional independent experiment.

Knowing the proposed targets of Eer1 is p97-associated DUB, an Ub blot of lysates from the supernatant or pellet fractions was used as a positive control for drug effect. Indeed, upon Eer1 treatment ubiquitinated proteins accumulated in both the supernatant and pellet lysates (Fig. 2A, right panel), which is in agreement with p97-associated DUB inhibition given that only a fraction of p97 molecules are membrane-bound (51, 52).

To further implicate DUBs in the dislocation of HC under physiological conditions, we tested the effect of PR-619, a non-selective, reversible DUB inhibitor (53), on the dislocation of *Ld. As a control for DUB inhibition, the amount of ubiquitinated proteins in both the supernatant and pellet fractions of the cells treated with PR-619 was augmented (Fig. 2B, right panel). To avoid a secondary effect of depletion of free Ub by prolonged inhibition of DUB activity, treatment was kept short for only 1 h. As shown in Fig. 2B, incubation of cells with PR-619 led to a stall of glycosylated *Ld in the pellet fraction. Thus, although it is known to also block proteasome degradation, the effect of PR-619 on ERAD of *Ld was strikingly similar to that of Eer1 and not MG132 that resulted in accumulation of deglyco-
Non-substrate Deubiquitination Required for ERAD Dislocation

FIGURE 3. Direct ubiquitination of the cytoplasmic tail of Ld as well as the tail itself is not required for dislocation of *Ld. A, nomenclature and schematic depiction of variant Ld molecules used in this study. Subscripted number shown with Lys, Cys, Ser, or Thr represents the number of each amino acid residue substituted in the ectodomain (ecto) and cytoplasmic (cyt) domains of Ld; TM, transmembrane. B, WT3 cells were co-transduced with cyt-BirA and one of the following BAP-tagged Ld: Ld wt, Ld tail∆K, or Ld tail∆KCST. Each of the above cells was incubated with 8.5 μM MG132 for 6 h before permeabilization, fractionation, and immunoprecipitation (IP) of Ld. *Ld molecules in the gel were detected as indicated. The total Ld blot shown in the lower panel served as a control for expression of different BAP-Ld molecules. C, left panel: cells in B were treated with 100 μg/ml of CHX and 60 μM MG132 for the indicated time before permeabilization, fractionation, and IP to recover BAP-Ld. Levels of dislocated deglycosylated *Ld in the cytosol fraction (sup) and total Ld in the membrane fraction (pellet) at different time point were detected as in B. Right panel, the rate of dislocation was quantified as the relative band intensities of dislocated, deglycosylated *Ld molecules at each time point in the lower gel to the intensity of time 0 of glycosylated Ld in the upper gel. D, cells co-expressing cyt-BirA and BAP-Ld (wt or ∆tail) were used in a CHX chase experiment as in C. Similar findings were observed in at least one additional independent experiment.

sylated *Ld primarily in the cytosol. The mechanistic implications of these findings are that Eer1 and PR-619 both affect dislocation by inhibiting DUB activity, implying a deubiquitination step is required for dislocation of HC in the absence of viral evasion.

Ubiquitination on the Tail of Ld Is Not Required for Its Dislocation—We next used Ld mutants to address the question of whether direct ubiquitination of substrate is required for dislocation. To this end, a set of N-terminal BAP-tagged Ld mutants that lack Ub conjugation sites were generated (Fig. 3A) and transduced into WT3 cells expressing cyt-BirA. To determine whether dislocation requires conventional Ub coupling on Lys residues in the cytoplasmic tail, a mutant BAP-Ld with a Lys-less tail (Ld tail∆K) was tested. In addition, to test whether dislocation might also require unconventional Ub coupling on hydroxyl- or thiol-containing amino acids, a mutant BAP-Ld with a KCST-less tail (Ld tail∆KCST) was also tested. Following treatment with MG132, like what was observed with wt *Ld, the majority of *Ld forms of both mutants were deglycosylated and detected in the cytosol (Fig. 3B, lanes 5 and 7 versus lane 3). This data suggests that ubiquitination on the tail is not required for HC dislocation. However, it remained possible that tail ubiquitination could promote dislocation efficiency perhaps by strengthening p97 association as suggested by studies of US11-induced dislocation of HC (17). To test the rates of dislocation, cells co-expressing cyt-BirA with Ld tail∆K, Ld tail∆KCST, or wt Ld molecules were treated with CHX and MG132 to stop protein synthesis and proteasome degradation for 0 to 3 h. Increases in the amounts of soluble, deglycosylated forms of *Ld tail∆K, *Ld tail∆KCST, or wt *Ld detected in the cytosol were monitored over 3 h to compare the relative rates of dislocation. Similar to what was seen in steady-state comparisons, none of the mutants displayed obviously altered rates of substrate dislocation (Fig. 3C). This data demonstrates that direct tail ubiquitination does not contribute to the dislocation efficiency. Although tail Ub modification was not required, it remained possible that a tail was still required for dislocation. Indeed this is the case with US11-induced dislocation that requires a tail, but not where tail Lys resides (18). To test whether a tail was required for HC dislocation, a BAP-Ld
Non-substrate Deubiquitination Required for ERAD Dislocation

FIGURE 4. Direct ubiquitination of Lys residues on the ectodomain of Ld is not required for dislocation but is critical for degradation by proteasome. A, left panel: cells co-expressing cyt-BirA and BAP-Ld (wt, ΔTail, or ΔK) were incubated with CHX (100 μg/ml) for the indicated times before being subjected to immunoprecipitation (IP) for Ld and detection of *Ld with SA-HRP/sp-ECL. Right panel: quantification of the decay rate of each type of Ld molecules is conducted by plotting the relative band intensities of glycosylated *Ld as a percentage of the intensity of time 0. B, left panel: cells in A were preincubated with 60 μM MG132 for 2 h to allow accumulation of dislocated deglycosylated *Ld in the cytosol. After extensive washing, these cells were subjected to chase in the presence of 10 μM E64 for the indicated time. The *Ld molecules were recovered from the supernatant of permeabilized cells by IP of Ld and visualized by blotting with SA-HRP/sp-ECL. A shorter exposure of *LdΔK blot is shown for better resolution. Right panel: quantification of the decay rate of each type of *Ld molecules is conducted by plotting the relative band intensities of deglycosylated *Ld in the gel as a percentage of the intensity of time 0. C, left panel: cells co-expressing cyt-BirA and BAP-Ld (ΔTail or ΔK), or expressing cyt-BirA only/BAP-Ld only as controls, were permeabilized and fractionated. The membrane-bound *Ld molecules in the pellet fractions were retrieved by two rounds of IPs: 1° IP with NeutrAvidin-agarose beads followed by denaturing with 0.5% SDS Tris-HCl buffer and then the 2° IP with anti-Ld (6A4-3-7). The precipitates were SDS-PAGE separated and blotted with anti-Ub (PM11), biotinylated secondary antibody, and SA-HRP to visualize *Ld and ubiquitinated *Ld. Right panel: cells expressing cyt-BirA only or co-expressing BirA and BAP-Ld (wt or ΔK) were treated with 50 μM MG132 for 2 h before permeabilization and fractionation. Cytosolic *Ld was retrieved by 1° and 2° IPs as described above from the supernatant fractions. Ubiquitinated and non-ubiquitinated *Ld in the precipitates were detected by Ub or SA-HRP blotting of a reducing gel. Nonspecific antibody bands (Ig) in the gels are indicated.

mutant lacking a tail (LdΔtail) was also tested. As shown in Fig. 3D, the LdΔtail was still dislocated into the cytosol with similar kinetics as wt Ld. Thus, neither tail ubiquitination nor a tail itself is required for complete dislocation of HC substrates.

Ubiquitination of Lys Resides on the Ectodomain of Ld Is Not Required for Dislocation but Is Required for Rapid Degradation by the Proteasome—An alternative hypothesis to tail-mediated dislocation of type I integral membrane protein is a partial dislocation model. In a partial dislocation model, ERAD substrates could expose Lys residues on the lumen portion of the substrate to the ubiquitination machinery in the cytosol. If this mechanism is used by physiological ERAD of MHC1 molecules, then the Lys residues in their ectodomains would be important for complete dislocation. To test this possibility, a CHX chase experiment (as above) was conducted with cells co-expressing cyt-BirA and a BAP-Ld mutant having all 13 Lys residues mutated to Arg (LdΔK). By monitoring the disappearance of deglycosylated *Ld species during the chase without MG132 treatment, glycosylated *LdΔK mutants were found to decay at a similar rate as the glycosylated wt *Ld and *LdΔtail molecules (Fig. 4A). This result implies that Lys resides in the ectodomain of HC are not required for dislocation. However, accumulation of deglycosylated forms was only seen with *LdΔK molecules (Fig. 4A). Of note, deglycosylated ERAD substrates are typically only found in the cytosol of cells treated with proteasome inhibitors and this experiment was carried out in the absence of MG132. Thus the unique detection of deglycosylated forms of *LdΔK was likely attributed to poor degradation. To confirm this conclusion, cells were treated with the reversible proteasome inhibitor MG132 for 3 h to allow accumulation of post-
Non-substrate Deubiquitination Required for ERAD Dislocation

A

B

FIGURE 5. DUB activity is required by dislocation of K-less Ld. A, upper panel: WT3 cells co-transduced with cyt-BirA and BAP-Ld were incubated with 40 μM MG132, PR-619, or a combination of the two for 1 h before permeabilization and fractionation. *Ld and total Ld from the supernatant (S) and pellet (P) fractions of each treatment were detected by immunoprecipitation (IP) of Ld followed by blotting (IB) with SA-HRP/sp-ECL or Ld mAb 64-3-7/std-ECL. Lower panel, lysates from the supernatant or pellet fractions before IP were blotted for ubiquitinated proteins to show the effect of DUB or proteasome inhibition by PR-619 or MG132. None of the treatments significantly altered the level of p97 in the supernatant or pellet fraction as shown in p97 blot. B, cells used in A were incubated with 20 μM MG132, 20 μM DBeQ, or a combination of the two for 2 h before permeabilization and fractionation. *Ld and total Ld in the lysates of the cells were determined as in A. DBeQ is a selective p97 inhibitor known to impair ERAD of orphan TCRs by ATP competition (66). Relative intensity of the bands of glycosylated and deglycosylated *Ld depends on p97 function (Fig. 5B), whereas the membrane-bound *Ld molecules with or without ectodomain lysines had no detectable Ub conjugation (Fig. 4C, left panel). The above findings were unexpected in light of our previous evidence that DUB activity is required for BAP-Ld dislocation. Indeed, we found that the DUB inhibitor PR-619 blocked the dislocation of *Ld mutants with no Lys residues in the entire molecule (Fig. 5A), although like a typical ERAD process, dislocation of *LdΔK depends on p97 function (Fig. 5B). Thus, these results demonstrate that direct ubiquitination/deubiquitination of Lys residues on HCs is not required for HC dislocation. In total our findings support the model that the processes of ubiquitination/deubiquitination required for dislocation and degradation of HC are distinct events and only the latter occurs directly on HC substrates during ERAD.

DISCUSSION

In this study we report using a sensitive site-specific biotinylation system to probe the dislocation of HC substrates subjected to ERAD in the absence of immune evasion proteins. Using this assay system evidence is presented that dislocation of HCs does not require potential Ub sites in its cytoplasmic tail, or Lys residues in its ectodomain. However, dislocation of HC does require DUB activity, and rapid degradation of HC post-dislocation requires Lys residues in the HC ectodomain. Our combined findings support the model that the physiologic dislocation and degradation during ERAD of HC require two separate and mechanistically distinct ubiquitination/deubiquitination events.

Much progress has been made in understanding how different ERAD substrates are dislocated. However, two remaining questions are when an ERAD substrate gets ubiquitinated and what specific role ubiquitination plays in dislocation? Past dogma has been that ubiquitination of substrates is required for proteasome-mediated degradation and occurs prior to the complete substrate extraction. In this model, Ub conjugates on substrates were proposed to function as either a handle or ratchet for p97-mediated extraction. However, the fact that the enzymatic domains of the ERAD-associated E2/E3 complexes are located in the cytosol raises the question of how soluble ERAD substrates or membrane substrates with no cytosolic Lys
Non-substrate Deubiquitination Required for ERAD Dislocation

residues are initially dislocated for exposure of their ectodomain to the ubiquitination machinery. A partial dislocation model is a potential solution and it is supported by the observation that ubiquitinated soluble substrates are sometimes caught on the ER membrane after blocking p97 activity (13, 15). However, some ERAD substrates stall inside of the ER in a non-ubiquitinated form under comparable conditions (14, 54). Most surprisingly, Ub conjugation prior to complete dislocation has been difficult to detect even for transmembrane proteins that have potential cytoplasmic Ub acceptor sites (18, 28).

Adding to the mystery of how ERAD substrates get ubiquitinated prior to dislocation, recent studies suggest that two rounds of ubiquitination/deubiquitination may be required, at least for a subset of ERAD substrates such as soluble protein R1331, as well as membrane proteins TCRs and MHCI HC (in the presence of US11) (26–28). The first round of ubiquitination/deubiquitination was hypothesized to be required for binding p97, after which Ub moieties have to be removed for substrates to pass through the narrow pore of p97 during dislocation. Analogously, the second round of ubiquitination/deubiquitination is required for proteasome association, after which Ub moieties are known to be removed prior to protein degradation (8). Our data reported here support the requirement for deubiquitination for dislocation of HC in the absence of immune evasion. However, the target of this deubiquitination appears not to be HC itself. Multiple viral proteins are known to target HC for ERAD via different strategies (29, 30). Although more efficient, evidence by others (35) and here suggest that ERAD induced by these viral proteins bypasses some of the critical steps of physiological pathway. More specifically, in the absence of viral proteins, we found less than 1% of the total HC pool is being dislocated and degraded. This observation likely reflects rate-limiting quality control mechanisms of substrate recognition that are bypassed by immune evasion proteins. Detection of the ubiquitination status on such a minor fraction of substrates is beyond the sensitivity range of the Ub blot. To circumvent this impediment, we adapted a cytosolic site-specific biotinylation system to quantitatively monitor the dislocation of wt HC and mutants lacking Ub acceptor sites. Indeed, by pharmacologically inhibiting dislocation or proteasome, this assay system allowed us to clearly identify and quantify the ER membrane-bound HCs destined for dislocation as well as the post-dislocated HCs destined for proteasome degradation. Surprisingly, we found that dislocation of the HC required neither a cytosolic tail nor ectodomain Lys residues. Nevertheless, the degradation of post-dislocated Lys-less HC was kinetically much slower than wt HCs suggesting that ubiquitination via its ectodomain Lys residues is important for the degradation of HCs by the proteasome. These findings also suggest that direct Ub conjugation of HC is not required for dislocation; and even if it is required, it occurs by a different mechanism than the Ub conjugation required for proteasome-mediated degradation of HC.

The likelihood that HCs are modified via non-Lys ubiquitination is low, but it is difficult to definitively rule out this possibility. For example, it has been reported that Ub conjugation of substrate could occur on an α-NH₂ group of the N terminus (55). However, the degron for N-terminal conjugation is thought to be located on the N termini of the substrates because the conjugation is often disrupted by insertion of an N-terminal tag (56). In our study, the N terminus of the HC was fused with a 15-amino acid biotin acceptor peptide that could potentially interfere with N-terminal ubiquitination. In addition, to the best of our knowledge there have been no reports of N terminally Ub-modified ERAD substrates. Alternatively, non-Lys residues such as Ser, Thr, or Cys on the substrate may serve as Ub acceptor sites (57). Evidence reported by us and other groups suggest that this type of non-canonical ubiquitination can occur on selected ERAD substrates and is potentiated by viral E3 ligase mK3 or cellular E3 ligase Hrd1 (38, 58, 59). However, in these studies whether the ubiquitination occurs prior to the dislocation was not addressed.

Indeed an attractive model for ERAD of HC initiated by cellular quality control is an indirect (trans) ubiquitination model in which an accessory protein associated with substrate rather than substrate itself is ubiquitinated. This indirect ubiquitination model was first proposed by Kopito and co-workers (60) when they unexpectedly found that Lys-less TCRα molecules could be efficiently degraded by the proteasome. Lack of evidence of direct ubiquitination on the substrate during dislocation was also observed in US11-induced ERAD of HC. Wiertz and co-workers (18) demonstrated that Lys residues on the HC are dispensable in US11-induced HC dislocation although a functional ubiquitination system was required for the dislocation to occur. In the current study, substrates undergoing ERAD were specifically detected and tracked during dislocation versus degradation. In contrast to inhibition of proteasome, which resulted in accumulation of deglycosylated HCs in the cytosol, incubation of cells with a non-selective DUB inhibitor led to stabilization of K-less *Ld molecules primarily in the membrane. This is similar to what we saw with Eer1 treatment, which is known to block p97 by probably interfering with p97-associated DUB (24). These combined observations indicate that a deubiquitination step is required for substrate dislocation prior to proteasome degradation. The target of this deubiquitination, however, is not likely the substrate itself based on our mutagenesis data. Taken together, these data thus support a model in which an indirect ubiquitination is required by substrate dislocation and direct ubiquitination is needed by proteasome degradation.

Based on these accumulating findings by us and others, we speculate that dislocation of ER membrane-bound HC is facilitated by ubiquitination/deubiquitination of a component of the dislocation complex. Consistent with this model published reports have shown that p97-associated DUBs interact with the components of dislocation machinery and can regulate activity of ERAD-associated E3 ligase (26, 61–63). These findings suggest that the ubiquitination status of the components of the dislocation complex may be critical for its assembly or function (64). In addition, Derlins and UBAC2, a newly identified UBA-domain containing ERAD component interacting with gsp78 and p97 recruiter UBXD8, were recently shown to be members of the rhomboid pseudoprotease family that may function similarly to rhomboid protease (23, 65). These authors proposed that Derlin might facilitate dislocation by unfolding a subset of ERAD substrates. If true, this conclusion also raises the possi-
bility that direct substrate ubiquitination may not be required for their extraction. Thus these published finding of others and our substrate mutagenesis data reported here support a role of non-substrate ubiquitination/deubiquitination in dislocation. An attractiveness of this model is that it would explain why only a few E3 ligases out of more than 600 are located in the ER yet are potentially responsible for ubiquitination of 1/3 of synthesized proteins.

Acknowledgment—We thank Dr. Janet Connolly for critical reading of the manuscript.

REFERENCES

1. Olzmann, J. A., Kopito, R. R., and Christianson, J. C. (2012) The mammalian endoplasmic reticulum-associated degradation system. Cold Spring Harb. Perspect. Biol. 10, 1101/1/1–1/19.

2. Hampton, R. Y., and Sommer, T. (2012) Finding the will and the way of ERAD substrate retrotranslocation. Curr. Opin. Cell Biol. 24, 460–466.

3. Tsai, Y. C., and Weissman, A. M. (2011) Ubiquitylation in ERAD. Revisiting to go forward? PLoS Biol. 9, e1001038.

4. Hampton, R. Y., and Sommer, T. (2012) Finding the will and the way of ERAD substrate retrotranslocation. Curr. Opin. Cell Biol. 24, 460–466.

5. Tsai, Y. C., and Weissman, A. M. (2011) Ubiquitylation in ERAD. Revisiting to go forward? PLoS Biol. 9, e1001038.

6. Hershko, A., and Ciechanover, A. (1998) The ubiquitin system.

7. Pickart, C. M. (2000) Ubiquitin in chains.

8. Pickart, C. M., and Cohen, R. E. (2004) Proteasomes and their kin. Proc. Natl. Acad. Sci. U.S.A. 101, 126–144.

9. Pickart, C. M. (2000) Ubiquitin in chains.

10. Hershko, A., and Ciechanover, A. (1998) The ubiquitin system.

11. Hampton, R. Y., and Sommer, T. (2012) Finding the will and the way of ERAD substrate retrotranslocation. Curr. Opin. Cell Biol. 24, 460–466.

12. Mehnert, M., Sommer, T., and Jarosch, E. (2010) ERAD ubiquitin ligases.

13. Bays, N. W., Wilhovsky, S. K., Goradia, A., Hodgkiss-Harlow, K., and Harris, R. A., van Leeuwen, D., Bouteiller, P. L., Wiertz, E. J., and Lenfant, F. (2003) Amino acid composition of α1/α2 domains and cytoplasmic tail of MHC class I molecules determine their susceptibility to human cytomegalovirus US11-mediated down-regulation. Eur. J. Immunol. 33, 1707–1716.

14. Furman, M. H., Loureiro, J., Ploegh, H. L., and Tortorella, D. (2003) Ubiquitination of the cytosolic domain of a type 1 membrane protein is not required to initiate its dislocation from the endoplasmic reticulum. J. Biol. Chem. 278, 34804–34811.

15. Williams, J. C., Kopito, R. R., and Christianson, J. C. (2012) The mammalian endoplasmic reticulum-associated degradation system. Cold Spring Harb. Perspect. Biol. 10, 1101/1/1–1/19.

16. Hampton, R. Y., and Sommer, T. (2012) Finding the will and the way of ERAD substrate retrotranslocation. Curr. Opin. Cell Biol. 24, 460–466.

17. Ye, Y., and Rape, M. (2009) Building ubiquitin chains. E2 enzymes at work. Annu. Rev. Biochem. 76, 425–479.

18. Pickart, C. M. (2000) ubiquitin in chains.

19. Ye, Y., and Rape, M. (2009) Building ubiquitin chains. E2 enzymes at work. Annu. Rev. Biochem. 76, 425–479.

20. Bays, N. W., Wilhovsky, S. K., Goradia, A., Hodgkiss-Harlow, K., and Harris, R. A., van Leeuwen, D., Bouteiller, P. L., Wiertz, E. J., and Lenfant, F. (2003) Amino acid composition of α1/α2 domains and cytoplasmic tail of MHC class I molecules determine their susceptibility to human cytomegalovirus US11-mediated down-regulation. Eur. J. Immunol. 33, 1707–1716.

21. Furman, M. H., Loureiro, J., Ploegh, H. L., and Tortorella, D. (2003) Ubiquitination of the cytosolic domain of a type 1 membrane protein is not required to initiate its dislocation from the endoplasmic reticulum. J. Biol. Chem. 278, 34804–34811.

22. Ye, Y., and Rape, M. (2009) Building ubiquitin chains. E2 enzymes at work. Annu. Rev. Biochem. 76, 425–479.

23. Furman, M. H., Loureiro, J., Ploegh, H. L., and Tortorella, D. (2003) Ubiquitination of the cytosolic domain of a type 1 membrane protein is not required to initiate its dislocation from the endoplasmic reticulum. J. Biol. Chem. 278, 34804–34811.

24. Ye, Y., and Rape, M. (2009) Building ubiquitin chains. E2 enzymes at work. Annu. Rev. Biochem. 76, 425–479.

25. Pickart, C. M. (2000) ubiquitin in chains.

26. Ye, Y., and Rape, M. (2009) Building ubiquitin chains. E2 enzymes at work. Annu. Rev. Biochem. 76, 425–479.

27. Pickart, C. M. (2000) ubiquitin in chains.

28. Ye, Y., and Rape, M. (2009) Building ubiquitin chains. E2 enzymes at work. Annu. Rev. Biochem. 76, 425–479.
Non-substrate Deubiquitination Required for ERAD Dislocation

40. Hughes, E. A., Hammond, C., and Cresswell, P. (1997) Misfolded major histocompatibility complex class I heavy chains are translocated into the cytoplasm and degraded by the proteasome. *Proc. Natl. Acad. Sci. U.S.A.* 94, 1896–1901

41. Petris, G., Vecchi, L., Bestagno, M., and Burrone, O. R. (2011) Efficient detection of proteins retro-translocated from the ER to the cytosol by *in vivo* histiobtnylation. *PLoS One* 6, e23712

42. Wang, X., Lybarger, L., Connors, R., Harris, M. R., and Hansen, T. H. (2004) Model for the interaction of gammaherpesvirus 68 RING-CH finger protein mK3 with major histocompatibility complex class I and the peptide-loading complex. *J. Virol.* 78, 8673–8686

43. DuBridge, R. B., Tang, P., Hisa, H. C., Leong, P. M., Miller, J. H., and Calos, M. P. (1987) Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. *Mol. Cell Biol.* 7, 379–387

44. Lybarger, L., Wang, X., Harris, M. R., Virgin, H. W., 4th, and Hansen, T. H. (2003) Virus subversion of the MHC class I peptide-loading complex. *Immunity* 18, 121–130

45. Beckett, D., Kovaleva, E., and Schatz, P. J. (1999) A minimal peptide substrate in biotin holoenzyme synthetase-catalyzed biotinylation. *Protein Sci.* 8, 921–929

46. Smith, J. D., Solheim, J. C., Carreno, B. M., and Hansen, T. H. (1995) Characterization of class I MHC folding intermediates and their disparate interactions with peptide and β2-microglobulin. *Mol. Immunol.* 32, 531–540

47. Barker, D. F., and Campbell, A. M. (1981) *The Proc. Natl. Acad. Sci. U.S.A.* 94, 1896–1901

48. Ushioda, R., Hoseki, J., Araki, K., Jansen, G., Thomas, D. Y., and Nagata, K. (2011) Identification of the PDI-family member ERp90 as an interaction partner of ERFAD. *EMBO Rep.* 10, 755–761

49. Scaglione, K. M., Zavodskzy, E., Todi, S. V., Patury, S., Xu, P., Rodriguez-Lebrón, E., Fischer, S., Konen, J., Djarmati, A., Peng, J., Gestwicki, J. E., and Paulson, H. L. (2011) Ubere2w and ataxin-3 coordinately regulate the ubiquitin ligase CHIP. *Mol. Cell* 43, 599–612

50. Sowa, M. E., Bennett, E. J., Gygi, S. P., and Harper, J. W. (2009) Defining the human deubiquitinating enzyme interaction landscape. *Cell* 138, 389–403

51. Liu, Y. and Ye, Y. (2012) Roles of p97-associated deubiquitinases in protein quality control at the endoplasmic reticulum. *Carr. Protein Pept. Sci.* 13, 436–446

52. Christianson, J. C., Oltzmann, J. A., Shaler, T. A., Sowa, M. E., Bennett, E. J., Richter, C. M., Tyler, R. E., Greenblatt, E. J., Harper, J. W., and Kopito, R. R. (2012) Defining human ERAD networks through an integrative mapping strategy. *Nat. Cell Biol.* 14, 93–105

53. Chou, T. F., Brown, S. J., Minond, D., Nordin, B. E., Li, K., Jones, A. C., Chase, P., Porubsky, P. R., Stoltz, B. M., Schoenen, F. J., Patricelli, M. P., Hodder, P., Rosen, H., and Deshaies, R. J. (2011) Reversible inhibitor of p97, DBeQ, impairs both ubiquitin-dependent and autophagic protein clearance pathways. *Proc. Natl. Acad. Sci. U.S.A.* 108, 4834–4839